Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Oritavancin matches vancomycin at treating skin infections

MRSA is among a group of infections for which a new single-dose antibiotic has been found as effective a treatment as vancomycin.

Oritavancin, now in a phase III trial, had similar efficacy as vancomycin at treating acute skin and skin-structure bacterial infections, including methicillin resistant Staphylococcus aureus (MRSA), the New England Journal of Medicine reported. Patients with a suspected gram positive skin infection received either a single intravenous 1,200mg dose of oritavancin (n=475) or seven to ten days of twice daily intravenous vancomycin (n=479). Oritavancin, a semi-synthetic lipoglycopeptide antibiotic, was as effective as vancomycin in all efficacy end points — such as reduction in lesion size and complete cure.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.11138997

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.